Benjamin F. Edwards & Company’s Gilead Sciences GILD Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q2 | $23.8M | Buy |
346,660
+11,890
| +4% | +$793K | 0.42% | 68 |
|
|
2024
Q1 | $24.5M | Buy |
334,770
+13,149
| +4% | +$1.01M | 0.45% | 60 |
|
|
2023
Q4 | $26.1M | Buy |
321,621
+263,264
| +451% | +$20.5M | 0.52% | 54 |
|
|
2023
Q3 | $4.37M | Sell |
58,357
-8,331
| -12% | -$641K | 0.17% | 116 |
|
|
2023
Q2 | $5.14M | Buy |
66,688
+29,266
| +78% | +$2.33M | 0.2% | 114 |
|
|
2023
Q1 | $3.1M | Sell |
37,422
-5,975
| -14% | -$495K | 0.13% | 165 |
|
|
2022
Q4 | $3.73M | Buy |
43,397
+459
| +1% | +$36.3K | 0.17% | 131 |
|
|
2022
Q3 | $2.65M | Buy |
42,938
+1,427
| +3% | +$90K | 0.13% | 160 |
|
|
2022
Q2 | $2.57M | Buy |
41,511
+5,325
| +15% | +$330K | 0.12% | 175 |
|
|
2022
Q1 | $2.15M | Buy |
36,186
+5,598
| +18% | +$358K | 0.1% | 213 |
|
|
2021
Q4 | $2.22M | Buy |
30,588
+374
| +1% | +$25.8K | 0.1% | 209 |
|
|
2021
Q3 | $2.11M | Buy |
30,214
+1,405
| +5% | +$98.7K | 0.11% | 193 |
|
|
2021
Q2 | $1.98M | Buy |
28,809
+183
| +0.6% | +$12.2K | 0.1% | 214 |
|
|
2021
Q1 | $1.85M | Sell |
28,626
-2,048
| -7% | -$132K | 0.1% | 215 |
|
|
2020
Q4 | $1.79M | Sell |
30,674
-1,283
| -4% | -$77.4K | 0.11% | 209 |
|
|
2020
Q3 | $2.02M | Buy |
31,957
+867
| +3% | +$60.1K | 0.14% | 176 |
|
|
2020
Q2 | $2.39M | Sell |
31,090
-539
| -2% | -$41.3K | 0.17% | 136 |
|
|
2020
Q1 | $2.37M | Sell |
31,629
-3,451
| -10% | -$238K | 0.2% | 125 |
|
|
2019
Q4 | $2.28M | Buy |
35,080
+799
| +2% | +$52K | 0.16% | 160 |
|
|
2019
Q3 | $2.17M | Buy |
34,281
+2,186
| +7% | +$143K | 0.17% | 152 |
|
|
2019
Q2 | $2.17M | Buy |
32,095
+3,240
| +11% | +$213K | 0.18% | 139 |
|
|
2019
Q1 | $1.88M | Sell |
28,855
-420
| -1% | -$27.9K | 0.17% | 140 |
|
|
2018
Q4 | $1.83M | Buy |
29,275
+1,038
| +4% | +$72.6K | 0.19% | 128 |
|
|
2018
Q3 | $2.18M | Sell |
28,237
-960
| -3% | -$72.5K | 0.21% | 117 |
|
|
2018
Q2 | $2.07M | Sell |
29,197
-1,286
| -4% | -$90.8K | 0.2% | 115 |
|
|
2018
Q1 | $2.3M | Buy |
30,483
+3,453
| +13% | +$274K | 0.23% | 100 |
|
|
2017
Q4 | $1.94M | Sell |
27,030
-607
| -2% | -$46.1K | 0.2% | 121 |
|
|
2017
Q3 | $2.24M | Sell |
27,637
-1,167
| -4% | -$89.2K | 0.27% | 90 |
|
|
2017
Q2 | $2.04M | Buy |
28,804
+2,908
| +11% | +$194K | 0.27% | 96 |
|
|
2017
Q1 | $1.76M | Sell |
25,896
-6,147
| -19% | -$432K | 0.26% | 91 |
|
|
2016
Q4 | $2.29M | Buy |
32,043
+3,104
| +11% | +$231K | 0.38% | 68 |
|
|
2016
Q3 | $2.29M | Sell |
28,939
-2,445
| -8% | -$199K | 0.4% | 57 |
|
|
2016
Q2 | $2.62M | Buy |
31,384
+8,409
| +37% | +$746K | 0.51% | 48 |
|
|
2016
Q1 | $2.11M | Buy |
22,975
+2,796
| +14% | +$252K | 0.44% | 50 |
|
|
2015
Q4 | $2.04M | Sell |
20,179
-477
| -2% | -$49.6K | 0.44% | 49 |
|
|
2015
Q3 | $2.03M | Buy |
20,656
+4,682
| +29% | +$520K | 0.44% | 50 |
|
|
2015
Q2 | $1.87M | Buy |
15,974
+1,952
| +14% | +$213K | 0.37% | 61 |
|
|
2015
Q1 | $1.38M | Buy |
14,022
+3,775
| +37% | +$383K | 0.29% | 78 |
|
|
2014
Q4 | $966K | Buy |
10,247
+2,589
| +34% | +$268K | 0.22% | 102 |
|
|
2014
Q3 | $815K | Buy |
7,658
+1,668
| +28% | +$163K | 0.2% | 119 |
|
|
2014
Q2 | $497K | Buy |
5,990
+2,625
| +78% | +$204K | 0.13% | 170 |
|
|
2014
Q1 | $238K | Buy |
3,365
+890
| +36% | +$69.8K | 0.07% | 258 |
|
|
2013
Q4 | $186K | Buy |
2,475
+1,200
| +94% | +$83.6K | 0.06% | 258 |
|
|
2013
Q3 | $80K | Hold |
1,275
| – | – | 0.03% | 336 |
|
|
2013
Q2 | $65K | Buy |
+1,275
| New | +$66.5K | 0.03% | 340 |
|
Other funds holding GILD
Benjamin F. Edwards & Company's GILD Position: Q2 2024 in Review
Benjamin F. Edwards & Company increased its Gilead Sciences (GILD) stake by 3.6% in Q2 2024, buying an estimated $793K and bringing the position to 346,660 shares worth $23.8M. The position accounts for 0.42% of the portfolio, ranked #68.
Benjamin F. Edwards & Company first reported a position in GILD in Q2 2013 and has held it in 45 quarters since. The position peaked at $26.1M in Q4 2023. 1,679 funds tracked by Wall St. Rank hold GILD as of Q2 2024.
- Benjamin F. Edwards & Company held 346,660 shares of Gilead Sciences worth $23.8M as of Q2 2024.
- Benjamin F. Edwards & Company bought 11,890 Gilead Sciences shares in Q2 2024, an estimated $793K.
- Gilead Sciences made up 0.42% of Benjamin F. Edwards & Company's portfolio in Q2 2024, its #68 holding.
- Benjamin F. Edwards & Company first reported a position in Gilead Sciences in Q2 2013 and has held it in 45 quarters since.
- Benjamin F. Edwards & Company's Gilead Sciences position peaked at $26.1M in Q4 2023.
- 1,679 funds tracked by Wall St. Rank held Gilead Sciences as of Q2 2024.
Based on Benjamin F. Edwards & Company's 13F filing for Q2 2024, filed 12 Aug 2024.